Remedee Labs' Solution becomes the first CE marked medical device approved for the treatment of fibromyalgia in Europe

Remedee Labs Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America Europe

clinical study, the results of which were presented at the annual meeting of the American College of Rheumatology (ACR) in 2023. The study's results showed that using the Remedee™ wristband for three 30-minute sessions per day produced a clear improvement in participants' quality of life, with a significant decrease in pain, generalized and physical fatigue, anxiety, and depression, as well as an improvement in sleep quality.

Remedee Labs' solution for patients with fibromyalgia has also been recognized in the United States, where it received Breakthrough Device Designation from the Food & Drug Administration (FDA) in 2022.

Remedee Labs will launch its dedicated medical offer for fibromyalgia patients on the French market in 2025.

About the Remedee Labs Solution

Remedee Labs offers an innovative, non-pharmacological solution to relieve the symptoms of fibromyalgia. The solution combines Remedee Labs' millimeter wave neuromodulation technology (endorphin stimulator wristband) with a comprehensive support program, which is a key part of chronic pain management.

About Remedee Labs

Remedee Labs is a start-up that specializes in non-pharmacological treatments for chronic pain. Founded by three experts in medical micro- and nanotechnology and biomedical research, Remedee Labs has developed an innovative solution to improve the lives of patients suffering from chronic pain.

Two clinical trials have demonstrated the effectiveness of Remedee Labs' technology as a treatment for chronic pain caused by arthritis and fibromyalgia.

More about Remedee Labs: https://remedeelabs.com

Contact:
Quentin RICHARD
[e-mail]

Logo - https://mma.prnewswire.com/media/2272538/Remedee_Labs_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/remedee-labs-solution-becomes-the-first-ce-marked-medical-device-class-iia-approved-for-the-treatment-of-fibromyalgia-in-europe-302247849.html